| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11376262 | FORMOSA | Method of treating an inflammatory or infectious disease |
May, 2036
(12 years from now) | |
| US10588913 | FORMOSA | Aqueous suspension agent containing glucocorticosteroid nanoparticles |
May, 2036
(12 years from now) | |
Clobetasol Propionate is owned by Formosa.
Clobetasol Propionate contains Clobetasol Propionate.
Clobetasol Propionate has a total of 2 drug patents out of which 0 drug patents have expired.
Clobetasol Propionate was authorised for market use on 04 March, 2024.
Clobetasol Propionate is available in suspension/drops;ophthalmic dosage forms.
Clobetasol Propionate can be used as treatment of inflammation.
The generics of Clobetasol Propionate are possible to be released after 09 May, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2027 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 04 March, 2024
Treatment: Treatment of inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
More Information on Dosage
CLOBETASOL PROPIONATE family patents
